Navigation Links
Webster Quadripolar Standard Deflectable Catheters

ProductsWebster Quadripolar Standard Deflectable Catheters
Company Biosense Webster, a Johnson & Johnson Company
Item Webster Quadripolar Standard Deflectable Catheters
Features 
  • 4, 5, 6 and 7 F sizes
  • Multiple electrode configurations
  • Numerous curve types (see side panel)
  • Plug, pin and molded connector type
    • Description Biosense Webster fixed curve catheters are available in a wide range of models and configurations, including multi-electrode tip configurations and several curve and connector types. Each catheter is handcrafted to precise and demanding specifications, using only the highest quality materials. A unique multi-step process incorporating proven wire-braiding and extrusion technologies results in the excellent torque and manueverability of Biosense Webster catheters.
    Info Biosense Webster, a Johnson & Johnson Company
    Customer Service: (800) 729-9010
    Web site: http://www.biosensewebster.com/

    Related medicine products :

    1. Webster Ruler
    2. Webster Small Anatomy Fixed Curve Catheters
    3. Webster Supra CS Decapolar (Coronary Sinus Fixed Curve Catheters)
    4. Webster Small Anatomy Deflectable Catheters
    5. Webster Coronary Sinus Deflectable Catheters
    6. Webster Octapolar Standard Deflectable Catheters
    7. Webster Quadrapolar Standard Deflectable Catheters
    8. Webster Decapolar Standard Deflectable Catheters
    9. Webster Decapolar Coronary Sinus Deflectable Catheters
    10. Webster Parahisian octapolar catheter
    11. Webster Santoro 20 Pole Fixed Curve Catheter
    Spinal Concepts has developed a versatile set of instruments intended to make posterior lumbar interbody fusion procedures precise, simple and quick every time. The Harmony PLIF Instrument Set is the
    Kerrison (Spurling) Laminectomy Rongeur. 15 cm - 6, thick footplate, large handle, 90 up-cutting, 2 mm wide.
    Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide.
    OSV II Smart ValveTM, Hakim, H-V Lumbar Valve system is the intelligent choice for meeting the complex demands of hydrocephalus shunting. Automatic pressure response causes the valve to adjust automa
    Medicine Products:
    (Date:10/13/2008)...ges Latinos to Get Tested, LOS ANGELES, Oct. 13 /...half of all newly diagnosed HIV/AIDS cases,reporte...ionally., -- A week of activities aimed at raisin...ting to coincide with National Latino AIDS Awarene...r Community, Our Responsibility: Latinos in Action...
    (Date:10/13/2008)...n ever before, study finds , , MONDAY,...ver are being treated for high blood pressure, say...nd Blood Institute. , The major factor in the d...igh blood pressure appears to be the obesity epide...dditional efforts are needed to prevent hypertensi...
    (Date:10/13/2008)...g advances study Study needed because of low... 13 /PRNewswire/ -- Advanced Circulatory Systems, ...ced today that it has received,an additional $1.5 ...,Health (NIH) to continue a study testing two devi...rdiac arrest outside a hospital. Parts of Oakland,...
    (Date:10/13/2008)...valve.com ) announced today that the expanded clin...aneous aortic valve replacement (PAVR) in high-ris...l patients at an accelerating pace. More than 1,80...ly 100 centers in 20 countries. , ...er 13, 2008 -- During the Monday Transcatheter Ao...
    Breaking Medicine News(10 mins):Health News:Nearly Half of Newly Diagnosed HIV/AIDS Cases in Los Angeles County Are Among Latinos 2Health News:Blood Pressure on the Rise in America 2Health News:Blood Pressure on the Rise in America 3Health News:3 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Health News: CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) : Highly encouraging registry data also presented at TCT 2008 2
    ...ofi-Aventis, one of the world's leading pharmaceut... Taxotere (docetaxel) improves survival in patient... clinical trial named TAX 327 compared Taxotere pl...one) plus prednisone. The study included a little ...
    ...nagers who use mobile phones for many hours a day ...ay develop psychological disorders, says a study t...s. // Francisca Lopez Torrecillas, a lecturer at t...chological assessment and treatment of the Univers...
    ...ian belief and knowledge are great healers and 140...rently in Delhi to study this value system. // "Th...tal role in dealing with mental health issues and ...re about it," said Patrick Bantman, a psychiatrist...
    ...en aiming to shed after-pregnancy pounds should ad...cording to a new study by Harvard researchers. // ...isk for weight gain in women,” said lead author Em...n that early postpartum period — such as diet, tel...
    Other Medicine News:Health News:Mobile Phone Addiction may Cause Psychological Problems 2Health News:Simple Solutions to Postpartum Weight Retention 2
    (Date:10/13/2008)... to Have Higher Sensitivity and Specificity, than...was the preferred test in all phas... 13 /- AT First Diagnostic LLC an,eme...ic test kits, today,announced that a recent evalua...f Research of the FirstVue(TM) HBSAG Test, was rel...
    (Date:10/13/2008)...- Facet Solutions, Inc. today,announc...nts from its US,IDE Pilot Study. The results show ... scores, and an 80% reduction in Visual Analog Sco...resident & CEO for Facet Solutions,added, "We are... far not,only demonstrate significant pain relief ...
    (Date:10/12/2008)...N, Oct. 12 /- Boston,Scient...ults from an analysis,of nearly 7,500 patients fro...esigned to confirm the performance of the TAXUS(R)...stem in real-world practice. The,two-year pooled A...nical,restenosis in patients with diabetes as effe...
    (Date:10/10/2008)...is Treatment with Kogenate FS Reduces the,Risk of ...No Pre-Existing,Joint Damage, BERKELEY, Calif., O...ced today that the U.S. Food and Drug Administrati...enate(R) FS Antihemophilic Factor,(Recombinant) to... risk of,joint damage in patients aged 0-16 years ...
    Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5Shingles Pain Treatment Will Benefit More Patients 2872 1Shingles Pain Treatment Will Benefit More Patients 2872 2Shingles Pain Treatment Will Benefit More Patients 2872 3Shingles Pain Treatment Will Benefit More Patients 2872 4Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 1Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 3Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 1Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 21New Health Knowledge Base and Semantic Search Engine Announced 25637 1New Health Knowledge Base and Semantic Search Engine Announced 25637 2
    ...Analysis Shows Statistically Significant Changes i...alif., March 26, 2007 /PRNewswire-FirstCall/ --,Al...e initial,results from its Phase IIa clinical tria...c patients with acute agitation. The 10 mg,dose of...rial,which was a statistically-significant reduct...
    ...d CAPTURE 2 Findings Suggest Improved Outcomes in ...26, 2007 /PRNewswire-FirstCall/ --,Positive 30-day...tid stenting can be performed with positive result...ience in real-world,(non-clinical trial) settings ...urgery. Interim results from the first 1,500,patie...
    Other Medicine Technology:Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 2Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 3Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 4Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 5Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating,Schizophrenic Patients With Acute Agitation 6Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 2Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 3Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and,Effective Treatment to Reduce Risk of Stroke 4